Overview Request Sample Pages Request Customization Download PDF
You are viewing: France Biosimilars Market analysis
Part of: Biosimilars Market (Global)

The France Biosimilars Market was valued at $1999.3 Million in 2025 and projected to reach to $2951.5 Million by 2030, representing a compound annual growth rate of 4.0%. France's biosimilars market is positioned for steady growth through 2030, driven by healthcare cost optimization initiatives and increasing physician confidence in biosimilar efficacy and safety.

France Biosimilars Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

France Biosimilars Market Trends and Insights

  • France is experiencing steady adoption of biosimilar therapies driven by healthcare cost pressures and regulatory support from European authorities.
  • The French market benefits from a mature healthcare infrastructure and increasing physician awareness of biosimilar efficacy and safety profiles. During the forecast period from 2025 to 2030, France is expected to see accelerated biosimilar penetration across oncology, immunology, and endocrinology segments.
  • France's reimbursement policies and generic substitution frameworks are creating favorable conditions for biosimilar market expansion.
  • The country's commitment to reducing healthcare expenditures while maintaining therapeutic quality positions France as a key growth market within the European biosimilars landscape..

Key Market Statistics

  • CAGR (2025-2030) 4.0% CAGR
  • Market Size, 2025 ~USD 1999.3 Million
  • Forecast, 2030 ~USD 2951.5 Million
  • Country France

France Biosimilars Market Overview

Market Size & Growth :

France's biosimilars market is valued at USD 1,999.3 million in 2025 and is projected to reach USD 2,951.5 million by 2030, with a steady CAGR of 4.0%.

Healthcare Cost Pressures :

French healthcare system's focus on cost containment is driving increased adoption of biosimilar therapies as alternatives to expensive originator biologics.

Regulatory Support :

European Medicines Agency (EMA) and French regulatory authorities provide robust frameworks supporting biosimilar approvals and market entry, facilitating market expansion.

Mature Healthcare Infrastructure :

France's advanced healthcare system, strong reimbursement mechanisms, and established distribution networks enable efficient biosimilar penetration across therapeutic areas.

France Biosimilars Market Dynamics

  • The French government's commitment to reducing pharmaceutical expenditures while maintaining treatment quality supports continued market expansion.
  • Reimbursement policies and EMA approvals will remain key growth catalysts.
  • However, growth rates remain moderate compared to global markets, reflecting France's already-established biosimilar adoption and market maturity.
  • Strategic partnerships and expanded therapeutic indications will further strengthen market penetration in oncology, immunology, and rheumatology segments..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Pharmaceuticals

    Top Technologies
    • Bioreactors
    • Analytical Testing
    • Bioanalytical Testing Services
    • Cell Counters
    • Data Management Services
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • SANOFI
    • Pfizer Inc.
    • NOVARTIS

      Key Takeaways

      • France's biosimilars market is valued at USD 1,999.3 million in 2025 with projected growth to USD 2,951.5 million by 2030.
      • France demonstrates a 4.0% CAGR, reflecting moderate but consistent market expansion driven by cost containment initiatives.
      • France's regulatory environment and reimbursement policies support increased biosimilar adoption across multiple therapeutic areas.
      • France is positioned as a significant growth market within Europe, benefiting from healthcare system maturity and physician acceptance.

      Biosimilars Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment USTEKINUMAB (Type)
      Forecast Period 2025–2030
      Growth Rate CAGR of 7.5% from 2025 to 2030
      Largest Segment MONOCLONAL ANTIBODIES (Drug Class)
      Market Size Base Year (Billions) ~USD 35.07 (2025)
      Revenue Forecast (Billions) ~USD 50.35 (2030)
      Segments Covered Drug Class, Type, Indication

      France Biosimilars Market Report Segmentation

      3 segment dimensions are covered across the global market.

      By Drug Class

      • Aflibercept
      • Anticoagulants
      • Erythropoietin
      • Etanercept
      • Follitropin
      • Glp-1 Antagonist
      • Granulocyte Colony-Stimulating Factor
      • Insulin
      • Interferons
      • Monoclonal Antibodies
      • Other Drug Class
      • Other Drug Classes
      • Recombinant Human Growth Hormone
      • Recombinant Human Growth Hormones
      • Teriparatide

      By Type

      • Adalimumab
      • Dupilumab
      • Infliximab
      • Other Monoclonal Antibodies
      • Pembrolizumab
      • Risankizumab
      • Rituximab
      • Trastuzumab
      • Ustekinumab

      By Indication

      • Blood Disorders
      • Chronic Diseases
      • Growth Hormone Deficiency
      • Infectious Diseases
      • Inflammatory & Autoimmune Diseases
      • Obesity
      • Oncology
      • Other Indications
      • Type Ii Diabetes

      Target Audience

      • Pharmaceutical Companies : Biosimilar manufacturers and originator biologic companies need France-specific market data to develop localized commercialization strategies and competitive positioning.
      • Healthcare Payers & Insurers : French health insurance providers and government agencies require market insights to optimize reimbursement policies and budget allocation for biosimilar therapies.
      • Medical Device & Biotech Investors : Investment firms and venture capitalists need France market analysis to evaluate biosimilar sector opportunities and portfolio company growth potential.
      • Healthcare Consultants : Management consulting firms advising pharmaceutical clients require detailed France market data to support strategic recommendations and market entry planning.
      • Hospital & Clinical Networks : French healthcare institutions need biosimilar market intelligence to inform procurement decisions, clinical protocols, and cost management initiatives.

      Key Companies in the France Biosimilars Market

      CompanyHQOwnershipStrongest segments
      PATHEON INCNetherlandsPrivate CompanymAbs (Adalimumab, Infliximab, Rituximab, Trastuzumab and others),Insulin,GCSF,
      ASTRAZENECAUnited KingdomPublic CompanymAbs (Adalimumab, Infliximab, Rituximab, Trastuzumab),Insulin,GLP-1,
      SANOFISpainPublic CompanyInsulin biosimilars and follow-on biologics,GLP-1 and obesity-adjacent biologic biosimilars,mAb biosimilars (adalimumab, infliximab, rituximab, trastuzumab),
      NOVO NORDISK A/SDenmarkPublic CompanyInsulin originators (human and analog),GLP-1 originators (incl. Wegovy and related),Rare disease biologics (incl. rhGH, rare endocrine),
      BRISTOL-MYERS SQUIBBUnited StatesPublic CompanymAbs (Oncology and Autoimmune originators),Anticoagulant (Eliquis and related),Cell and Gene / Advanced Therapies,
      ALLERGAN PLCIrelandPrivate CompanymAbs (Adalimumab, Infliximab, Rituximab, Trastuzumab),Insulin,GCSF,
      BIOGENUnited StatesPublic CompanymAbs – Adalimumab (Autoimmune),mAbs – Etanercept (Autoimmune),mAbs – Infliximab (Autoimmune),
      GENENTECHUnited StatesPrivate CompanymAbs – Trastuzumab,mAbs – Rituximab,mAbs – Other (including Avastin-class and related),
      GILEAD SCIENCES INCUnited StatesPublic CompanymAbs-related oncology exposure (Trodelvy, cell therapy adjacencies),Autoimmune / inflammatory exposure via partnerships,Metabolic and GLP-1–adjacent exposure,
      MERCK KGAAUnited StatesPublic CompanymAbs-related (Adalimumab, Infliximab, Rituximab, Trastuzumab),Insulin and GLP-1–related,GCSF and anticoagulant-related,
      SHIREIrelandPrivate CompanymAbs (Adalimumab, Infliximab, Rituximab, Trastuzumab),GCSF,Insulin,
      FLUOR CORPORATIONUnited StatesPublic CompanymAbs (Adalimumab, Infliximab, Rituximab, Trastuzumab and other mAbs),Insulin,GLP-1,
      CELGENE CORPORATIONUnited StatesPrivate CompanyOncology originators at risk from mAb and related biosimilars,Autoimmune and immunoscience originators,Hematology supportive and niche therapies,
      SANDOZ GROUP AGSwitzerlandPublic CompanymAbs (Adalimumab, Infliximab, Rituximab, Trastuzumab),GCSF,Insulin,
      PFIZER INC.IndiaPublic CompanymAbs (Adalimumab, Infliximab, Rituximab, Trastuzumab),GCSF,Insulin,
      AMGEN INC.United StatesPublic CompanymAbs – Oncology (e.g., MVASI, trastuzumab, rituximab class),mAbs – Autoimmune (e.g., AMJEVITA/AMGEVITA, adalimumab class),GCSF (e.g., NEULASTA biosimilar class),
      CELLTRION INC.South KoreaPublic CompanymAbs – Autoimmune (Infliximab, Adalimumab, SC formulations),mAbs – Oncology (Rituximab, Trastuzumab, Bevacizumab),Ophthalmology and Immunology (Omlyclo, Eydenzelt, Steqeyma, Avtozma),
      BIOCONIndiaPublic CompanyInsulin and insulin analog biosimilars,Oncology mAbs (including trastuzumab, rituximab, others),Autoimmune mAbs (including adalimumab, infliximab),
      DR. REDDY’S LABORATORIES LTD.IndiaPublic CompanymAbs (Adalimumab, Infliximab, Rituximab, Trastuzumab),GCSF,Insulin,
      ELI LILLY AND COMPANYUnited StatesPublic CompanyInsulin (Basaglar, Humalog, Humulin family),GLP-1 and incretin-based (Mounjaro, Trulicity, orforglipron pipeline),Oncology biologics (Cyramza, Erbitux, TYVYT, Verzenio, others),
      TEVA PHARMACEUTICAL INDUSTRIES LTD.IsraelPublic Company
      STADA ARZNEIMITTEL AGGermanyPrivate CompanymAbs (Adalimumab, Infliximab, Rituximab, Trastuzumab),GCSF,Insulin,
      SAMSUNG BIOLOGICSSouth KoreaPublic CompanymAbs biosimilars (Adalimumab, Infliximab, Rituximab, Trastuzumab and other mAbs),GCSF and other hematology biosimilars,Insulin biosimilars,
      AMNEAL PHARMACEUTICALS LLCUnited StatesPublic CompanymAbs (Adalimumab, Infliximab, Rituximab, Trastuzumab),GCSF,Insulin,
      COHERUS BIOSCIENCESUnited StatesPublic CompanyG-CSF (UDENYCA / Neulasta biosimilar),Oncology mAbs / Immunotherapies (LOQTORZI, Casdozokitug, CHS-114, toripalimab-related),Other biosimilars and partnered biologics,
      BIO THERA SOLUTIONSChinaPublic CompanymAbs – Autoimmune (Adalimumab, Infliximab, Tocilizumab-class, others),mAbs – Oncology (Bevacizumab-class and other oncology mAbs),Other Biologics for Autoimmune/Cardiovascular/Eye (non-mAb and novel biologics),

      PATHEON INC

      Patheon Inc. is a Netherlands-based pharmaceutical company with 9,100 employees operating as a private entity. The company provides contract manufacturing and development services to the pharmaceutical industry.

      ASTRAZENECA

      AstraZeneca is a United Kingdom-based public pharmaceutical company founded in 1992 with 96,100 employees. It focuses on the discovery, development, and commercialization of prescription medicines across multiple therapeutic areas.

      SANOFI

      Sanofi is a Spain-based public pharmaceutical company founded in 1994 with 74,846 employees. The company engages in the research, development, and distribution of pharmaceutical products and vaccines.

      NOVO NORDISK A/S

      Novo Nordisk A/S is a Denmark-based public company founded in 1923 with 67,900 employees. The company specializes in diabetes care, obesity management, and other chronic disease treatments.

      BRISTOL-MYERS SQUIBB

      Bristol-Myers Squibb is a United States-based public pharmaceutical company founded in 1887 with 32,500 employees. It develops and manufactures prescription medicines for oncology, immunology, cardiovascular, and cell therapy.

      ALLERGAN PLC

      Allergan PLC is an Ireland-based private pharmaceutical company founded in 1983 with 17,400 employees. The company specializes in eye care, neurotoxin, and aesthetic pharmaceutical products.

      BIOGEN

      Biogen is a United States-based public biotechnology company founded in 1978 with 7,500 employees. It focuses on discovering, developing, and delivering therapies for neurological and neurodegenerative diseases.

      GENENTECH

      Genentech is a United States-based private biotechnology company founded in 1976 with 11,186 employees. The company specializes in the discovery and development of biopharmaceutical products.

      GILEAD SCIENCES INC

      Gilead Sciences Inc. is a United States-based public biopharmaceutical company founded in 1987 with 17,000 employees. It develops and commercializes antiviral drugs, immunology products, and oncology medicines.

      MERCK KGAA

      Merck KGaA is a United States-based public company founded in 1668 with 59,077 employees. It operates in pharmaceuticals, life sciences, and performance materials sectors.

      SHIRE

      Shire is an Ireland-based private pharmaceutical company founded in 1986 with 23,044 employees. The company specializes in rare diseases, neuroscience, and gastrointestinal treatments.

      FLUOR CORPORATION

      Fluor Corporation is a United States-based public engineering and construction company founded in 1912 with 22,995 employees. It provides services to the energy, chemicals, and pharmaceutical industries.

      CELGENE CORPORATION

      Celgene Corporation is a United States-based private biopharmaceutical company founded in 1986 with 8,852 employees. It develops and commercializes therapies for cancer, inflammatory, and immunological diseases.

      SANDOZ GROUP AG

      Sandoz Group AG is a Switzerland-based public pharmaceutical company founded in 1886 with 22,356 employees. It specializes in generic and biosimilar medicines.

      PFIZER INC.

      Pfizer Inc. is an India-based public pharmaceutical company founded in 1950 with 1,244 employees. The company manufactures and distributes pharmaceutical products.

      AMGEN INC.

      Amgen Inc. is a United States-based public biotechnology company founded in 1980 with 31,500 employees. It discovers, develops, manufactures, and delivers human therapeutics with a focus on oncology, cardiovascular disease, and inflammation.

      CELLTRION INC.

      Celltrion Inc. is a South Korea-based public biopharmaceutical company founded in 2002 with 2,680 employees. It specializes in the development and manufacturing of biosimilar and biopharmaceutical products.

      BIOCON

      Biocon is an India-based public biopharmaceutical company founded in 1978 with 16,447 employees. It develops and manufactures biopharmaceuticals, including insulins, monoclonal antibodies, and recombinant proteins.

      DR. REDDY’S LABORATORIES LTD.

      Dr. Reddy's Laboratories Ltd. is an India-based public pharmaceutical company founded in 1984 with 27,527 employees. It manufactures and markets generic pharmaceuticals, active pharmaceutical ingredients, and specialty drugs.

      ELI LILLY AND COMPANY

      Eli Lilly and Company is a United States-based public pharmaceutical company founded in 1876 with 50,000 employees. It discovers, develops, manufactures, and markets pharmaceutical products across multiple therapeutic areas.

      TEVA PHARMACEUTICAL INDUSTRIES LTD.

      Teva Pharmaceutical Industries Ltd. is an Israel-based public pharmaceutical company founded in 1901 with 32,008 employees. It develops and manufactures generic and specialty pharmaceutical products.

      STADA ARZNEIMITTEL AG

      STADA Arzneimittel AG is a Germany-based private pharmaceutical company founded in 1895 with 11,500 employees. It develops and manufactures generic and branded pharmaceutical products.

      SAMSUNG BIOLOGICS

      Samsung Biologics is a South Korea-based public biopharmaceutical company founded in 2011 with 5,195 employees. It provides contract manufacturing services for biopharmaceutical products.

      AMNEAL PHARMACEUTICALS LLC

      Amneal Pharmaceuticals LLC is a United States-based public pharmaceutical company founded in 2002 with 8,700 employees. It develops and manufactures generic and specialty pharmaceutical products.

      COHERUS BIOSCIENCES

      Coherus BioSciences is a United States-based public biopharmaceutical company founded in 2010 with 145 employees. It focuses on the development and commercialization of biosimilar medicines.

      BIO THERA SOLUTIONS

      Bio Thera Solutions is a China-based public biopharmaceutical company founded in 2003 with 1,426 employees. It engages in the research, development, and manufacturing of biopharmaceutical products.

      Reasons to Buy this Report

      • Localized Market Intelligence : Gain France-specific insights on biosimilar adoption rates, reimbursement policies, and competitive dynamics unavailable in global market reports.
      • Regulatory Landscape Analysis : Understand EMA and French regulatory pathways, approval timelines, and compliance requirements specific to the French market entry strategy.
      • Strategic Market Positioning : Identify growth opportunities in France's therapeutic segments, pricing strategies, and distribution channels to optimize market penetration.
      • Competitive Benchmarking : Analyze France-specific competitor strategies, market share distribution, and differentiation tactics among biosimilar manufacturers.
      • Investment & Expansion Planning : Support business decisions with accurate France market forecasts, cost-benefit analyses, and risk assessments for market entry or expansion.

      Frequently asked questions

      What is the current size of France's biosimilars market?

      France's biosimilars market is estimated at USD 1,999.3 million in 2025.

      What is the projected market size for France's biosimilars by 2030?

      France's biosimilars market is forecast to reach USD 2,951.5 million by 2030.

      What is the growth rate of France's biosimilars market?

      France's biosimilars market is expected to grow at a compound annual growth rate of 4.0% from 2025 to 2030.

      What factors are driving biosimilar adoption in France?

      France's biosimilar adoption is driven by healthcare cost pressures, regulatory support, mature healthcare infrastructure, and increasing physician awareness of biosimilar safety and efficacy.

      Which therapeutic areas show the strongest biosimilar growth in France?

      Oncology, immunology, and endocrinology segments are expected to experience accelerated biosimilar penetration in France during the forecast period.

      RESEARCH METHODOLOGY

      This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global biosimilars market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

      Secondary Research

      Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the biosimilars market. The secondary sources used for this study are the US Food and Drug Administration (US FDA), the European Medicines Agency (EMA), World Health Organization (WHO), the National Institute for Health and Care Excellence (NICE), Health Canada, Australian Government Department of Health and Aged Care, Ministry of Food and Drug Safety (MFDS) (South Korea), the Brazilian Health Regulatory Agency (ANVISA), Health Products Regulatory Authority (HPRA), the Ministry of Health, Labour, and Welfare (Japan), the Central Drugs Standard Control Organization (CDSCO), the National Medical Products Administration (NMPA) (China), Purple Book, GaBI Generics and Biosimilars Initiative, the National Center for Biotechnology Information (NCBI), IQVIA, Academic Journals, Company Websites, Annual Reports, SEC Filings, Investor Presentations, and MarketsandMarkets Analysis. These sources also obtained key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

      Primary Research

      Following an initial assessment of the global biosimilars market landscape through secondary research, comprehensive primary research was undertaken. This involved conducting in-depth interviews with market experts from the demand side, including stakeholders from pharmaceutical and biotechnology firms, CROs, CMOs, and academic and research institutions. Additionally, interviews were held with key supply-side participants, such as C-suite and senior executives, product managers, and marketing and sales leaders from prominent manufacturers, distributors, and channel partners. The research covered six major geographical regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while 30% involved demand-side experts. Data collection methods included structured questionnaires, email correspondence, online surveys, personal interviews, and telephonic discussions to understand the market dynamics comprehensively. The following is a breakdown of the primary respondents:

      The following is a breakdown of the primary respondents:

      Biosimilars Market

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both bottom-up and top-down approaches were used to estimate and validate the total size of the biosimilars market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

      • A list of the major global players operating in the biosimilars market was generated.
      • The revenues generated from their biosimilars product have been determined through annual reports and secondary sources (including paid databases)
      • The products were mapped according to the segments of the market. Percentage shares and splits were determined based on the revenue contributed to each segment. This was verified using secondary sources and by industry experts.
      • All assumptions, approaches, and individual shares/revenue estimates were validated through expert interviews.

      Global Biosimilars Market Size: Bottom-up and Top-down Approach

      Biosimilars Market

      Data Triangulation

      After arriving at the market size from the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

      Market Definition

      Biosimilars are complex biological products that exhibit high similarity to their reference (originator) biologics, demonstrating comparable efficacy, safety, and quality. These therapeutic alternatives can be developed and brought to market once the patent protection of the original biologic elapses. Per the US FDA's definition, a biosimilar is a biological product highly similar to an already approved reference product, with no clinically significant differences in safety, purity, or potency, despite minor variations in clinically inactive components. The biosimilars market encompasses currently available products and those anticipated for launch within the forecasting horizon. This market includes a diverse array of therapeutic areas, notably oncology and inflammatory and autoimmune diseases, where biosimilars are increasingly utilized as treatment options, providing cost-effective alternatives to reference biologics while ensuring patient safety and therapeutic efficacy.

      Stakeholders

      • Manufacturers and distributors of biosimilar products
      • Pharmaceutical and biotechnology companies
      • Contract research organizations (CROs)
      • Contract Development & Manufacturing Organizations (CDMOs)
      • Market research and consulting firms
      • R&D centers
      • Academic & research institutes
      • Regulatory agencies
      • Health insurers and payers
      • Venture capitalists
      • Government organizations
      • Industry associations & professional societies
      • Private & government funding organizations 

      Report Objectives

      • To define, describe, and forecast the biosimilars market based on drug class, indication, and region
      • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets1 concerning individual growth trends, prospects, and contributions to the biosimilars market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions—North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To profile the key players in the global biosimilars market and comprehensively analyze their product portfolios, market positions, and core competencies
      • To track and analyze competitive developments such as product approvals and launches, expansions, agreements, and collaborations in the biosimilars market
      • To benchmark players within the biosimilars market using the company evaluation matrix framework, which analyzes market players based on various parameters within the broad categories of business and service strategy

       

      Get the Full Biosimilars Market Report

      Full forecast, segment splits, and company analysis for all Biosimilars Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status